Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EUSA buys up Innocoll antibiotic and pain control lines:

This article was originally published in Clinica

Executive Summary

Collagen implant technology developer Innocoll has sold its Collatamp G antibiotic surgical implant and wound dressing lines, as well as its CollaRx bupivacaine pain control implant, to specialty pharmaceutical company EUSA Pharma. The transaction sees Doylestown, Pennsylvania-based EUSA gain worldwide rights to the products, except in the US - although it does have an option to the US rights for CollaRx bupivacaine. Innocoll (Oxford, UK) will also transfer its European sales and marketing force (which sells to 20 European territories) and worldwide distribution network (covering 25 other non-European countries) to EUSA. Innocoll will continue to manufacture the products and supply them to EUSA, in return for an undisclosed upfront fee, future milestone payments, and an equity investment from the latter in Innocoll's parent company. Collatamp G is a biodegradable collagen sponge implant used in drug delivery, whereas CollaRx bupivacaine is designed to provide post-operative pain relief and reduce opioid dependency.

You may also be interested in...

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Hair Supplement Linked To Cases Of Severe Hepatitis In France

France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.

AZ Will Sideline ‘Lucky Mistake’ Data To Secure COVID-19 Vaccine Approval

A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts